Who owns Ionis Pharmaceuticals (IONS)? Superinvestor holders
4 superinvestors of the 157 tracked here hold Ionis Pharmaceuticals (IONS) in their latest 13F filing, with $584M between them. Tweedy, Browne team gives it the most weight: 6.52% of the reported portfolio. In their latest reported quarter, Cathie Wood and John Overdeck and David Siegel (founders) added; Tweedy, Browne team reduced.
Ron Baron sold out of it in their latest quarter.
Key facts
- Superinvestors holding it
- 4 of 157
- Biggest holder
- John Overdeck and David Siegel (founders), $300.4M
- Largest weight
- Tweedy, Browne team, 6.52%of their portfolio
- Combined value
- $584M
- Bought last quarter
- 2
- Sold last quarter
- 2
From each investor's latest 13F filing: 92 investors report Q3 2026, 65 investors report Q2 2026. Latest filing in this set: Nov 16, 2026.
| # | Investor | Share of their portfolio | Value | Shares | Last quarter | Shares moved | Quarter |
|---|---|---|---|---|---|---|---|
| 1 | Tweedy, Browne teamTweedy, Browne Company | 6.52% | $80.1M | 1.79M | ▼ Reduced 21% | −486.83K | Q3 2026 |
| 2 | Julian and Felix BakerBaker Bros. Advisors | 0.81% | $162.4M | 2.05M | No change | 0 | Q2 2026 |
| 3 | Cathie WoodARK Invest | 0.24% | $41.2M | 923.16K | ▲ Added 207% | +622.39K | Q3 2026 |
| 4 | John Overdeck and David Siegel (founders)Two Sigma Investments | 0.22% | $300.4M | 6.73M | ▲ Added 7.6% | +475.17K | Q3 2026 |
Sold out last quarter
- Ron Baronwas $1.1M · Q3 2026
Quarter by quarter
| Quarter | Filings in | Holders | Combined shares | Combined value | Bought | Sold |
|---|---|---|---|---|---|---|
| Q3 2026 | 92 | 3 | 9.44M | $421.7M | 2 | 2 |
| Q2 2026 | 157 | 4 | 10.88M | $862.8M | 3 | 0 |
| Q1 2026 | 157 | 5 | 10.47M | $786.5M | 2 | 2 |
| Q4 2025 | 157 | 5 | 7.34M | $580.9M | 2 | 2 |
| Q3 2025 | 157 | 4 | 4.1M | $268.5M | 3 | 1 |
| Q2 2025 | 157 | 2 | 3.79M | $149.8M | 0 | 3 |
| Q1 2025 | 156 | 3 | 4.34M | $131M | 0 | 2 |
| Q4 2024 | 156 | 3 | 4.63M | $161.9M | 1 | 3 |
A quarter's holder count is out of the filings in for that quarter — the newest quarter fills up over the 45 days investors have to file.
Each holder's shares
| Investor | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| John Overdeck and David Siegel (founders) | 6.73M | 6.25M | 5.86M | 2.66M | — | — | — | — |
| Tweedy, Browne team | 1.79M | 2.28M | 2.28M | 2.46M | 2.9M | 2.89M | 2.98M | 3.25M |
| Cathie Wood | 923.16K | 300.77K | 288.72K | 422.97K | 631.22K | 900.32K | 1M | 1.03M |
| Julian and Felix Baker | · | 2.05M | 2.05M | 1.79M | 566.8K | — | 357.92K | 357.92K |
| Andrew Spokes | — | — | 4.8K | 4.8K | 4.8K | — | — | — |
A dash: the investor filed for that quarter without this stock among their largest positions. A dot: no filing of theirs for that quarter is on file.
Questions and answers
Which superinvestors own IONS?
In their latest 13F filings: Tweedy, Browne team (6.52% of the portfolio, $80.1M), Julian and Felix Baker (0.81% of the portfolio, $162.4M), Cathie Wood (0.24% of the portfolio, $41.2M), John Overdeck and David Siegel (founders) (0.22% of the portfolio, $300.4M).
Who bought IONS last quarter?
Cathie Wood (added 207%), John Overdeck and David Siegel (founders) (added 7.6%). “Last quarter” is each investor's latest reported quarter.
Who sold IONS last quarter?
Reduced: Tweedy, Browne team (21% fewer shares). Sold out entirely: Ron Baron (was $1.1M).
How current is this?
It comes from Form 13F, which large managers file within 45 days of each quarter's end; the latest filing read here was made on Nov 16, 2026. Positions may have changed since, and a 13F shows long US-listed positions only.
Learn
Cite this page
Funkfolio, “Who owns Ionis Pharmaceuticals (IONS)? Superinvestor holders”, data as of 16 November 2026. https://funkfolio.com/stock/IONS/superinvestors
Underlying data: SEC EDGAR, Form 13F-HR filings of the investors tracked here.
Source: SEC EDGAR, Form 13F-HR filings of the 157 investors tracked here, matched to IONS by security number and name. Only each investor's 150 largest positions per filing are read, so a small line in a very long portfolio is not seen, and a security held without a matched ticker cannot be found. “Last quarter” compares share counts with the investor's previous filing. Share counts are restated for a split only where a tracked investor held the stock through it. Filings appear up to 45 days after a quarter ends and show long US-listed positions only; this is not advice.